Avadomide is an orally administered small molecule that binds cereblon and redirects the Cullin-4 RING E3 ubiquitin ligase to degrade the transcription factors Aiolos and Ikaros. It is being studied in non-Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
CC-122, BMS-986381
Drug type
Small molecule (Molecular glue degrader)
Targets
cereblon (CRBN), Aiolos (IKZF3) (binding partner it blocks), Ikaros (IKZF1) (binding partner it blocks)
Mechanism
Degrader of cereblon (CRBN)
Pathways
Cullin-4 RING E3 ubiquitin ligase degradation, interferon-stimulated gene derepression, IL-2 production and T-cell costimulation, NK cell activation
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.